Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Esomeprazole in Symptomatic GERD with Partial PPI Response
NCT02743949Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of vonoprazan in gastroesophageal reflux disease (GERD), sponsored by Takeda. Started Jul 2016; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02743949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743949.